DE602005016189D1 - Verfahren zum Evaluieren und Behandeln von Krebs - Google Patents

Verfahren zum Evaluieren und Behandeln von Krebs

Info

Publication number
DE602005016189D1
DE602005016189D1 DE602005016189T DE602005016189T DE602005016189D1 DE 602005016189 D1 DE602005016189 D1 DE 602005016189D1 DE 602005016189 T DE602005016189 T DE 602005016189T DE 602005016189 T DE602005016189 T DE 602005016189T DE 602005016189 D1 DE602005016189 D1 DE 602005016189D1
Authority
DE
Germany
Prior art keywords
evaluating
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005016189T
Other languages
English (en)
Inventor
Mitch Raponi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Janssen Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Diagnostics LLC filed Critical Janssen Diagnostics LLC
Publication of DE602005016189D1 publication Critical patent/DE602005016189D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DE602005016189T 2004-07-01 2005-07-01 Verfahren zum Evaluieren und Behandeln von Krebs Active DE602005016189D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/883,436 US20050003422A1 (en) 2003-07-01 2004-07-01 Methods for assessing and treating cancer

Publications (1)

Publication Number Publication Date
DE602005016189D1 true DE602005016189D1 (de) 2009-10-08

Family

ID=35058443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016189T Active DE602005016189D1 (de) 2004-07-01 2005-07-01 Verfahren zum Evaluieren und Behandeln von Krebs

Country Status (14)

Country Link
US (1) US20050003422A1 (de)
EP (1) EP1611890B1 (de)
JP (1) JP2006014739A (de)
KR (1) KR20060048684A (de)
CN (1) CN1721553A (de)
AR (1) AR049564A1 (de)
AT (1) ATE440604T1 (de)
AU (1) AU2005202520A1 (de)
BR (1) BRPI0502433A (de)
CA (1) CA2512493A1 (de)
DE (1) DE602005016189D1 (de)
DK (1) DK1611890T3 (de)
MX (1) MXPA05007207A (de)
PT (1) PT1611890E (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504403A1 (en) * 2004-05-06 2005-11-06 Veridex, Llc Prognostic for hematological malignancy
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
AU2008225130A1 (en) * 2007-03-12 2008-09-18 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8296867B2 (en) * 2008-03-21 2012-10-30 Bauer Hockey, Inc. Helmet for a hockey or lacrosse player
WO2010093465A1 (en) * 2009-02-11 2010-08-19 Caris Mpi, Inc. Molecular profiling of tumors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CA2806112C (en) * 2010-07-28 2023-03-21 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019032489A1 (en) * 2017-08-07 2019-02-14 Kura Oncology, Inc. METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
US20210231666A1 (en) * 2018-06-06 2021-07-29 La Jolla Institute For Immunology Cd33 monocytes as a biomarker

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0946565B1 (de) 1996-12-20 2003-10-15 Tovarischestvo S Ogranichennoi Otvetstvennostju "Tabifarm" Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12-olid-hydrochlorid
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
MXPA04004072A (es) * 2001-10-30 2004-09-06 Johnson & Johnson Metodos para valorar y tratar leucemia.
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
EP1502962A3 (de) * 2003-07-01 2006-01-11 Veridex, LLC Methoden zur Einschätzung und zur Behandlung von Krebserkrankungen

Also Published As

Publication number Publication date
AU2005202520A1 (en) 2006-01-19
JP2006014739A (ja) 2006-01-19
PT1611890E (pt) 2009-09-29
BRPI0502433A (pt) 2006-04-04
KR20060048684A (ko) 2006-05-18
EP1611890B1 (de) 2009-08-26
CN1721553A (zh) 2006-01-18
US20050003422A1 (en) 2005-01-06
AR049564A1 (es) 2006-08-16
CA2512493A1 (en) 2006-01-01
EP1611890A1 (de) 2006-01-04
DK1611890T3 (da) 2009-11-16
MXPA05007207A (es) 2006-05-22
ATE440604T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
DE602005016189D1 (de) Verfahren zum Evaluieren und Behandeln von Krebs
DE602006012823D1 (de) Vorrichtung und verfahren zum neusynthetisieren von signalen
DE602005011934D1 (de) Vorrichtung zum Einfangen von Kügelchen und Verfahren und Vorrichtung zum Anordnen von Kügelchen
DE602005017318D1 (de) Verfahren und Vorrichtung zum Bereitstellen von Entwurfsdaten
DE602006019769D1 (de) Verfahren und gerät zum falten von artikeln
DE112005003862A5 (de) Verfahren und Vorrichtungen zum Bereitstellen von Stapelchipelementen
DE112006004263A5 (de) Verfahren und Vorrichtung zum Stapeln von DRAMS
DE602006008553D1 (de) Vorrichtung und Verfahren zum Fördern von Werkstücken
DE602005012917D1 (de) Verfahren und Vorrichtung zum Umformen
ATE482150T1 (de) Verfahren zum zusammenhalten von verpackungen und zum halten von komponenten daran
DE602006003496D1 (de) Vorrichtung und Verfahren zum Trocknen von Wäsche
DE602006004532D1 (de) Vorrichtung und Verfahren zum Trockenreinigen
DE602005004280D1 (de) Verfahren zum ziehen von sic-einkristallen und sic-einkristall
DE602006008520D1 (de) Verfahren und Vorrichung zum Gruppieren von Produkten
DE112008003045A5 (de) Verfahren und Vorrichtung zum Behandeln von Schlamm
DE602006020904D1 (de) Verfahren zum testen von antigen
DE502005003858D1 (de) Verfahren zum detektieren und entfernen von fremdkörpern
DE102005033305A8 (de) Werkzeug und Verfahren zum Bearbeiten von Geröll
DE112007003786A5 (de) Verfahren und Vorrichtung zum Durchführen von Auswahl-Operationen
DE502005010348D1 (de) Verfahren und werkzeugeinrichtung zum umformen
DE602006013148D1 (de) Verfahren zum austrocknen und/oder entlauben von glyphosateresistenten kulturen
DE602005012045D1 (de) Verfahren und Vorrichtung zum Befördern von Werkstücken
DE602005013541D1 (de) Verfahren und gerät zum trimmen von faserigen substraten
FI20045449A (fi) Menetelmä ja laitteisto hakkeen käsittelemiseksi
DE112007002256A5 (de) Heizvorrichtung und Verfahren zum Heizen von Gegenständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition